Literature DB >> 25700387

Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer.

Marcello C Ambrogi1, Olivia Fanucchi2, Paolo Dini3, Franca Melfi3, Federico Davini3, Marco Lucchi3, Gabriele Massimetti4, Alfredo Mussi1.   

Abstract

The main aim of this study was to compare radiofrequency ablation (RFA) and wedge resection in terms of disease recurrence and survival, as intent-to-treat therapy for stage I nonsmall cell lung cancer (NSCLC) in marginal or non-surgical candidates. 121 high-risk patients, treated for stage I NSCLC with wedge resection (n=59) or RFA (n=62) in a 7-year period, were analysed. Age, sex, comorbidity score, performance status, forced expiratory volume in 1 s and forced vital capacity values, body mass index, T-stage and histology were evaluated as possible risk factors affecting disease recurrence and survival. At a median follow-up of 36 and 42 months for wedge resection and for RFA (p=0.232), local recurrence rate was 2 and 23%, respectively (p=0.002). The 1-, 2- and 5-year overall survival (disease-free interval) rates were 100% (96%), 96% (90%) and 52% (76%) for wedge resection, and 93% (87%), 72% (63%), and 35% (55%) for RFA (p=0.044 and p=0.01, respectively). None of the analysed parameters was found to be risk factor for disease recurrence and survival, except stage T2, which significantly affected disease-recurrence, overall and cancer-related survival and disease-free interval in the RFA group. Whenever possible, surgical resection, even if limited, should be preferred due to its higher disease control and survival rates. RFA can be considered a valid option for inoperable patients, especially for those with stage T1N0.
Copyright ©ERS 2015.

Entities:  

Mesh:

Year:  2015        PMID: 25700387     DOI: 10.1183/09031936.00188014

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  10 in total

1.  A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032).

Authors:  Michael S Kent; Sumithra J Mandrekar; Rodney Landreneau; Francis Nichols; Nathan R Foster; Thomas A DiPetrillo; Bryan Meyers; Dwight E Heron; David R Jones; Angelina D Tan; Sandra Starnes; Joe B Putnam; Hiran C Fernando
Journal:  Ann Thorac Surg       Date:  2016-04-19       Impact factor: 4.330

2.  Body mass index and mortality in lung cancer patients: a systematic review and meta-analysis.

Authors:  J Wang; H Xu; S Zhou; D Wang; L Zhu; J Hou; J Tang; J Zhao; S Zhong
Journal:  Eur J Clin Nutr       Date:  2017-05-17       Impact factor: 4.016

3.  Validating margin status in lung wedge resection for clinical stage I non-small cell lung cancer.

Authors:  Noriyoshi Sawabata; Akikazu Kawase; Nobumasa Takahashi; Takeshi Kawaguchi; Tetsukan Woo; Yuichi Saito; Satoshi Shiono; Noriyuki Matsutani
Journal:  Surg Today       Date:  2018-06-19       Impact factor: 2.549

4.  Stereotactic Body Radiation Therapy Versus Nonradiotherapeutic Ablative Procedures (Laser/Cryoablation and Electrocautery) for Early-Stage Non-Small Cell Lung Cancer.

Authors:  Michael J Baine; Richard Sleightholm; Beth K Neilsen; David Oupický; Lynette M Smith; Vivek Verma; Chi Lin
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

5.  Comparison between radiofrequency ablation and sublobar resections for the therapy of stage I non-small cell lung cancer: a meta-analysis.

Authors:  Shuang Chen; Shize Yang; Shun Xu; Siyuan Dong
Journal:  PeerJ       Date:  2020-05-21       Impact factor: 2.984

Review 6.  Advances and controversies in the management of early stage non-small cell lung cancer.

Authors:  Angel Cilleruelo-Ramos; Esther Cladellas-Gutiérrez; Carolina de la Pinta; Laura Quintana-Cortés; Paloma Sosa-Fajardo; Felipe Couñago; Xabier Mielgo-Rubio; Juan Carlos Trujillo-Reyes
Journal:  World J Clin Oncol       Date:  2021-12-24

7.  Comparison of stereotactic body radiotherapy and radiofrequency ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Ran Zhang; Jingjing Kang; Shengxiang Ren; Ligang Xing; Yaping Xu
Journal:  Ann Transl Med       Date:  2022-01

8.  Sublobar resection versus ablation for stage I non-small-cell lung cancer: a meta-analysis.

Authors:  Yong Li; Fang Yang; Ya-Yong Huang; Tao Wang
Journal:  J Cardiothorac Surg       Date:  2022-02-11       Impact factor: 1.637

9.  Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis.

Authors:  Wei-Yu Yang; Yu He; Qikang Hu; Muyun Peng; Zhe Zhang; Shouzhi Xie; Fenglei Yu
Journal:  Front Oncol       Date:  2022-08-23       Impact factor: 5.738

10.  [Treatment of Stage Ia Non-small Cell Lung Cancer in Patients: 
Comparison of Ablation and Sub-lobectomy].

Authors:  Heng Zhao; Kun Fan; Hongyi Wang; Bohao Liu; Yixing Li; Runyi Tao; Zhiyu Wang; Jia Zhang; Junke Fu; Guangjian Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-07-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.